Ceregene Lab

Press Releases


04.23.08
Ceregene Announces Two Key Additions to Leadership Team
01.07.08
 Ceregene to Present at JPMorgan 26th Annual Healthcare Conference
12.12.07
 Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease
12.06.07
 Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
11.14.07
 Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
06.21.07
 Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson's Disease
05.02.07
 Ceregene Presents Interim Phase I Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
04.16.07
 Ceregene Presents Long Term Follow-Up Data from Phase I Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients
04.13.07
 Growth Factor Therapy Appears to Improve Symptoms in Mid-Stage Parkinson's Disease
10.10.06
 Ceregene Announces Promising Phase I Results from Gene Therapy Trial for Parkinson's Disease
10.10.06
 Michael J. Fox Foundation Awards $1.9 Million to Support Ceregene Phase II Gene Therapy Clinical Trial.
06.13.06
 Gene Therapy Injected into the Brains' of Mice with Huntington's Disease Protects Neurons, Stop Degeneration and Improves Behavioral Function
11.28.05 Michael J. Fox Foundation Announces Funding For Ceregene Phase-1 Gene Therapy Clinical Trial
09.21.05 Ceregene Reports Initiation Of Phase 1 Clinical Trial Of Novel Gene Therapy For Patients With Parkinson's Disease
07.12.05
 Ceregene Adds Biotech Executive John Walker To Its Board Of Directors
04.25.05
 Ceregene Scientific Co-Founder Publishes Alzheimer's Disease Clinical Trial Results in Nature Medicine
02.09.05
 Ceregene Promotes Raymond Bartus to Senior Vice President and Chief Operating Officer
08.04.04
 Ceregene Announces $32 Million Series B Financing
04.29.04
 Ceregene Confirms Plans to Further Develop Alzheimer's Disease Gene Therapy
02.11.04
 Ceregene Announces Issuance of Broad Patent for Neurologic Gene Therapy
08.07.03
Ceregene Acquires Rights to ALS Gene Therapy From the Salk Institute
03.26.03
 Ceregene Licenses Genes From Genentech For Neurological Gene Therapies
12.04.02
 Ceregene exclusively licenses neurturin gene from Washington University
11.14.02
 Ceregene elects new vice president.
10.15.02
 Ceregene Awarded SBIR Grant From NIH for Alzheimer's Research
04.18.02
 Ceregene expands into new facility.
03.07.02
 Ceregene announces additions to management team...
01.28.02
 Ceregene-licensed Alzheimer's gene therapy featured on CNN...
04.10.01
 Ceregene confirms treatment of first patient in Phase 1 study...
04.02.01
 Dr. Jeffrey Ostrove appointed president of Ceregene...
01.11.01
 Cell Genesys launches new cns gene therapy subsidiary...